Immediate-Release Versus Controlled-Release Formulations: Pharmacokinetics of Newer Antidepressants in Relation to Nausea
J Clin Psychiatry 2003;64(suppl 18):14-19
© Copyright 2017 Physicians Postgraduate Press, Inc.
Access to this article is available to valid users
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Register: If you do not have one already, register for a free account.
Newer antidepressants are generally as efficacious as but often have fewer side effects than their
predecessors such as the tricyclic antidepressants and monoamine oxidase inhibitors. These newer
antidepressants include the selective serotonin reuptake inhibitors (SSRIs) citalopram, escitalopram,
fluoxetine, fluvoxamine, paroxetine, and sertraline; venlafaxine, a serotonin-norepinephrine reuptake
inhibitor; and bupropion, a selective norepinephrine and dopamine reuptake inhibitor. Most of these
antidepressants have half-lives that enable them to be administered as infrequently as 1 to 3 times per
day. To further improve upon the ease of use, controlled-release formulations of bupropion, fluoxetine,
paroxetine, and venlafaxine have been manufactured. Potential pharmacokinetic advantages of
these formulations include lower peak plasma drug concentrations and smaller fluctuations between
peak and trough plasma drug concentrations, which might influence the tolerability of these medications.
Tolerability advantages seen with some of these medications include diminished nausea.
The 3 controlled-release agents that are designed to be taken daily—bupropion, paroxetine, and venlafaxine—are associated with lower incidences of nausea overall and nausea leading to treatment discontinuation
than are their immediate-release formulations. However, the rates of nausea are similar
with both formulations of fluoxetine, despite higher peak plasma drug concentrations and greater fluctuation
between peak and trough plasma drug concentrations with fluoxetine weekly than with fluoxetine
daily. Although the connection has not been proven, more stable pharmacokinetic profiles might
be the cause for the low occurrence of nausea with some controlled-release newer antidepressants.